We are live on ! Find out more
EGRX

Eagle Pharmaceuticals, Inc.
EGRX

Delisted

EGRX was delisted on the 2nd of October, 2024.

Back to rankings

119 hedge funds and large institutions have $1.04B invested in Eagle Pharmaceuticals, Inc. in 2015 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 50 increasing their positions, 34 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

47% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 34

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

0% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 26

1% less funds holding

Funds holding: 120 → 119 (-1)

4% less capital invested

Capital invested by funds: $1.08B → $1.04B (-$39.8M)

31% less call options, than puts

Call options by funds: $7.06M | Put options by funds: $10.2M

Holders
119
Holders Change
-1
Holders Change %
-0.83%
% of All Funds
3.32%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.17%
New
26
Increased
50
Reduced
34
Closed
26
Calls
$7.06M
Puts
$10.2M
Net Calls
-$3.17M
Net Calls Change
+$964K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$21.5M
2
HCMT
Highland Capital Management (Texas)
Texas
+$19.9M
3
CCM
Consonance Capital Management
New York
+$14.2M
4
Invesco
Invesco
Georgia
+$10.5M
5
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$6.15M

Top Sellers

Rank Fund Capital Flow
1
BIM
Bogle Investment Management
Massachusetts
-$12.9M
2
PA
Perceptive Advisors
New York
-$9.15M
3
ARTA
A.R.T. Advisors
New York
-$3.85M
4
Marshall Wace
Marshall Wace
United Kingdom
-$3.84M
5
AL
AJO LP
Pennsylvania
-$3.83M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$4.57M -$404K -4,859 -7%
Two Sigma Advisers
27
Two Sigma Advisers
New York
$4.47M +$4.1M +49,300 +452%
PI
28
Putnam Investments
Massachusetts
$4.25M +$1.51M +18,150 +46%
QI
29
QS Investors
New York
$4.23M – – –
NIP
30
Nicholas Investment Partners
California
$3.93M +$109K +1,314 +3%
RFC
31
Russell Frank Company
Washington
$3.81M +$18K +216 +0.4%
CCM
32
Century Capital Management
Massachusetts
$3.65M -$2.28M -27,432 -36%
William Blair & Company
33
William Blair & Company
Illinois
$3.54M +$327K +3,934 +9%
AQR Capital Management
34
AQR Capital Management
Connecticut
$3.3M +$1.43M +17,162 +63%
GH
35
GAM Holding
Switzerland
$3.16M +$508K +6,100 +17%
Deutsche Bank
36
Deutsche Bank
Germany
$3.15M +$1.83M +22,043 +108%
EI
37
EAM Investors
California
$3.1M -$2.97M -35,758 -46%
HCM
38
Highbridge Capital Management
New York
$2.87M -$1.09M -13,104 -25%
PP
39
PDT Partners
New York
$2.68M +$809K +9,718 +37%
Susquehanna International Group
40
Susquehanna International Group
Pennsylvania
$2.35M +$1.57M +18,820 +145%
TCIM
41
TIAA CREF Investment Management
New York
$2.27M -$100K -1,204 -4%
BIM
42
BlackRock Investment Management
Delaware
$2.13M -$38.6K -464 -2%
BA
43
BlackRock Advisors
Delaware
$2.13M -$123K -1,482 -5%
SAM
44
Sectoral Asset Management
Quebec, Canada
$2.08M -$1.41K -17 -0.1%
TCM
45
Timpani Capital Management
Wisconsin
$2M -$1.86M -22,364 -45%
PAM
46
Panagora Asset Management
Massachusetts
$1.99M +$381K +4,578 +21%
Charles Schwab
47
Charles Schwab
California
$1.94M +$1.15M +13,827 +111%
Wellington Management Group
48
Wellington Management Group
Massachusetts
$1.94M +$1.74M +20,950 +395%
Ameriprise
49
Ameriprise
Minnesota
$1.8M +$448K +5,382 +28%
SLG
50
Stanley-Laman Group
Pennsylvania
$1.78M – – –
1
2
3 4 5

EGRX Hedge Fund Activity: Q3 2015 in Review

119 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q3 2015, worth a combined $1.04B — down 3.7% from $1.08B a quarter earlier.

Fund positioning in EGRX was balanced in Q3 2015: 26 funds opened new positions, 26 closed out, 50 added to existing stakes and 34 trimmed.

The largest buyer was Vanguard Group, adding an estimated $21.5M. The largest seller was Bogle Investment Management, exiting entirely with an estimated $12.9M sold.

  • 119 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q3 2015, down from 120 in Q2 2015.
  • Funds reported $1.04B of Eagle Pharmaceuticals, Inc. stock for Q3 2015, down 3.7% quarter-over-quarter.
  • 26 funds opened new Eagle Pharmaceuticals, Inc. positions in Q3 2015 and 26 closed out, a net change of 0 holders.
  • The largest Eagle Pharmaceuticals, Inc. buyer in Q3 2015 was Vanguard Group, an estimated $21.5M added.
  • The largest Eagle Pharmaceuticals, Inc. seller in Q3 2015 was Bogle Investment Management, an estimated $12.9M sold.

Based on aggregated 13F filings for Q3 2015.